1. Home
  2. RYOJ vs CVKD Comparison

RYOJ vs CVKD Comparison

Compare RYOJ & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYOJ
  • CVKD
  • Stock Information
  • Founded
  • RYOJ 2015
  • CVKD 2022
  • Country
  • RYOJ Japan
  • CVKD United States
  • Employees
  • RYOJ N/A
  • CVKD N/A
  • Industry
  • RYOJ Professional Services
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • RYOJ Consumer Discretionary
  • CVKD Health Care
  • Exchange
  • RYOJ Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • RYOJ 32.5M
  • CVKD 29.5M
  • IPO Year
  • RYOJ 2025
  • CVKD 2023
  • Fundamental
  • Price
  • RYOJ $2.42
  • CVKD $12.36
  • Analyst Decision
  • RYOJ
  • CVKD Strong Buy
  • Analyst Count
  • RYOJ 0
  • CVKD 1
  • Target Price
  • RYOJ N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • RYOJ 228.0K
  • CVKD 30.1K
  • Earning Date
  • RYOJ 01-01-0001
  • CVKD 08-11-2025
  • Dividend Yield
  • RYOJ N/A
  • CVKD N/A
  • EPS Growth
  • RYOJ 72.91
  • CVKD N/A
  • EPS
  • RYOJ 0.13
  • CVKD N/A
  • Revenue
  • RYOJ $11,576,848.00
  • CVKD N/A
  • Revenue This Year
  • RYOJ N/A
  • CVKD N/A
  • Revenue Next Year
  • RYOJ N/A
  • CVKD N/A
  • P/E Ratio
  • RYOJ $18.54
  • CVKD N/A
  • Revenue Growth
  • RYOJ 5.60
  • CVKD N/A
  • 52 Week Low
  • RYOJ $2.30
  • CVKD $5.70
  • 52 Week High
  • RYOJ $3.75
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • RYOJ N/A
  • CVKD 56.27
  • Support Level
  • RYOJ N/A
  • CVKD $12.58
  • Resistance Level
  • RYOJ N/A
  • CVKD $13.93
  • Average True Range (ATR)
  • RYOJ 0.00
  • CVKD 0.99
  • MACD
  • RYOJ 0.00
  • CVKD 0.31
  • Stochastic Oscillator
  • RYOJ 0.00
  • CVKD 78.23

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: